Radiolabeled Compounds for Diagnosis and Treatment of Cancer
Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developi...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
| LEADER | 04408namaa2201129uu 4500 | ||
|---|---|---|---|
| 001 | doab77048 | ||
| 003 | oapen | ||
| 005 | 20220111 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 220111s2021 xx |||||o ||| 0|eng d | ||
| 020 | |a 9783036524269 | ||
| 020 | |a 9783036524276 | ||
| 020 | |a books978-3-0365-2426-9 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-2426-9 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 072 | 7 | |a PN |2 bicssc | |
| 720 | 1 | |a Kumar, Krishan |4 edt | |
| 720 | 1 | |a Kumar, Krishan |4 oth | |
| 245 | 0 | 0 | |a Radiolabeled Compounds for Diagnosis and Treatment of Cancer |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 online resource (262 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Chemistry |2 bicssc | |
| 650 | 7 | |a Research and information: general |2 bicssc | |
| 653 | |a 123,124,125,131I-labeled molecules and biomolecules | ||
| 653 | |a 124I-labeled monoclonal antibodies | ||
| 653 | |a 188Re-liposome | ||
| 653 | |a AAZTA | ||
| 653 | |a adrenergic receptor | ||
| 653 | |a aprepitant | ||
| 653 | |a biomolecules | ||
| 653 | |a breast | ||
| 653 | |a cancer | ||
| 653 | |a cancer imaging and therapy | ||
| 653 | |a cholecystokinin-2 receptor | ||
| 653 | |a cleavable linkers | ||
| 653 | |a DPP | ||
| 653 | |a EpCAM | ||
| 653 | |a FAP | ||
| 653 | |a fluorine-18 | ||
| 653 | |a hypopharyngeal cancer | ||
| 653 | |a imaging | ||
| 653 | |a imaging pharmaceuticals | ||
| 653 | |a immunoPET imaging pharmaceuticals | ||
| 653 | |a iodine | ||
| 653 | |a kidney uptake | ||
| 653 | |a lutetium-177 | ||
| 653 | |a microRNA | ||
| 653 | |a minigastrin | ||
| 653 | |a molecular imaging | ||
| 653 | |a monoclonal antibodies | ||
| 653 | |a n/a | ||
| 653 | |a neurokinin 1 receptor antagonist | ||
| 653 | |a neutral endopeptidase (NEP) | ||
| 653 | |a NGS | ||
| 653 | |a peptides | ||
| 653 | |a PET | ||
| 653 | |a PET probes | ||
| 653 | |a PIB | ||
| 653 | |a positron emission tomography | ||
| 653 | |a positron emission tomography (PET) | ||
| 653 | |a PREP | ||
| 653 | |a production processes | ||
| 653 | |a prostate-specific membrane antigen (PSMA) | ||
| 653 | |a proteins | ||
| 653 | |a pyrazoles | ||
| 653 | |a radioiodination | ||
| 653 | |a radioiodine labeling | ||
| 653 | |a radiolabeling | ||
| 653 | |a radionuclide | ||
| 653 | |a radionuclide chelators | ||
| 653 | |a radionuclide therapy | ||
| 653 | |a radionuclides | ||
| 653 | |a radiopharmaceuticals | ||
| 653 | |a radiotracer | ||
| 653 | |a radiotracers | ||
| 653 | |a renal brush border enzymes | ||
| 653 | |a repeated therapy | ||
| 653 | |a SA | ||
| 653 | |a scandium-44 | ||
| 653 | |a somatostatin analogs | ||
| 653 | |a SPECT | ||
| 653 | |a target-specific biomolecules | ||
| 653 | |a targeted radiotherapy | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/77048 |7 0 |z Open Access: DOAB: description of the publication |
| 856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/4658 |7 0 |z Open Access: DOAB, download the publication |